The non-Hodgkin lymphoma therapeutics market was estimated to be worth USD 9.4 billion globally in 2022, and a compound annual growth rate (CAGR) of 8.1% is anticipated over the course of the projected period. The number of non-Hodgkin lymphoma patients, the most dangerous and deadly type of cancer, is rising along with the number of promising pipeline medications.
Growing healthcare...
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek